Vitality
PT-141 / Oxytocin
Peptide blend
PT-141 and Oxytocin blend
Research context
This preparation combines PT-141, a melanocortin receptor agonist, with oxytocin, a nonapeptide acting at the oxytocin receptor. The two act at unrelated receptor systems. Each component is characterised independently in the literature.
Common assays: Component identity by LC-MS · Purity per component
Specification
| Designation | Peptide blend |
|---|---|
| Full name | PT-141 and Oxytocin blend |
| Components | PT-141 (Bremelanotide) · Oxytocin |
| Formats | 15 mL Nasal Spray · 15 mL Oral Spray |
| Solubility | Supplied in metered spray format |
| Storage | Refrigerated 2–8 °C, protected from light |
| Current lot | OXY10N1125 → |
Common questions
How is a two-component blend verified?
Each component is identified and quantified separately by LC-MS and RP-HPLC, with results reported per component on the certificate.
Same pathway
Related compounds
PT-141
Bremelanotide
A cyclic heptapeptide melanocortin receptor agonist studied in MC3R and MC4R signalling.
Melanotan II
Melanotan-II
A cyclic α-MSH analogue studied as a non-selective melanocortin receptor agonist.
Kisspeptin
KISS1-derived peptide
A decapeptide fragment of the KISS1 gene product, studied in GnRH neuron signalling.